Defilade Capital Management, L.P. — 13F Holdings & Portfolio
CIK 2088557 · latest 13F-HR filed 2026-08-14
Defilade Capital Management, L.P. manages $746.9M in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LLY (6.28%), PFE (5.71%), VEEV (5.62%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 20 new positions and exited 12; 6 existing positions rose in reported value and 10 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 46.5%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Jun 26, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| DEFILADE CAPITAL HOLDINGS, LLC Control | GENERAL PARTNER since Nov 2024 | 75% or more | Domestic Entity |
| FORMAN, JONATHAN, LOUIS Control | CHIEF INVESTMENT OFFICER, LIMITED PARTNER since Nov 2024 | Less than 5% | Individual |
| LaPorta, Mark, Anthony Control | CHIEF DATA SCIENTIST since Nov 2024 | Less than 5% | Individual |
| Metke, Patrick, Phillips Control | CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER since Nov 2024 | Less than 5% | Individual |
| FORMAN, JONATHAN, LOUIS Control Indirect owner via DEFILADE CAPITAL HOLDINGS, LLC | SOLE MEMBER since Nov 2024 | 75% or more | Individual |
Ownership & leadership changes · 2 filings with changes since Jul 29, 2025
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedFORMAN, JONATHAN, LOUIS · title CHIEF INVESTMENT OFFICER → CHIEF INVESTMENT OFFICER, LIMITED PARTNER
- ChangedDEFILADE CAPITAL HOLDINGS, LLC · title GENERAL PARTNER, LIMITED PARTNER → GENERAL PARTNER
- ListedDEFILADE CAPITAL HOLDINGS, LLC · GENERAL PARTNER, LIMITED PARTNER · 75% or more · control person
- ListedFORMAN, JONATHAN, LOUIS · CHIEF INVESTMENT OFFICER · Less than 5% · control person
- ListedFORMAN, JONATHAN, LOUIS · SOLE MEMBER · 75% or more · indirect via DEFILADE CAPITAL HOLDINGS, LLC · control person
- ListedLaPorta, Mark, Anthony · CHIEF DATA SCIENTIST · Less than 5% · control person
- ListedMetke, Patrick, Phillips · CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ELI LILLY & CO$27.8M +146.3%
- PTC THERAPEUTICS INC$9.7M +38.0%
- ELEDON PHARMACEUTICALS INC$2.9M +26.5%
- OCULAR THERAPEUTIX INC$2.0M +16.1%
- COGENT BIOSCIENCES INC$1.7M +12.2%
Top Trims
- ZIMMER BIOMET HOLDINGS INC-$25.0M -47.8%
- GLOBUS MED INC-$19.5M -63.9%
- ICU MED INC-$17.3M -52.8%
- DENALI THERAPEUTICS INC-$16.0M -61.4%
- REVOLUTION MEDICINES INC-$15.2M -49.5%
New Positions
- VEEVA SYS INC$42.0M
- BIOMARIN PHARMACEUTICAL INC$39.0M
- BAXTER INTL INC$31.1M
- INSULET CORP$26.9M
- THERMO FISHER SCIENTIFIC INC$26.0M
Exited Positions
- SCHEIN HENRY INC$46.0M
- BECTON DICKINSON & CO$43.9M
- DEXCOM INC$33.8M
- INTUITIVE SURGICAL INC$31.2M
- NEUROCRINE BIOSCIENCES INC$27.7M
Defilade Capital Management, L.P. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ELI LILLY & CO | LLY | 532457108 | $46.9M | 6.28% | 39,086 | SH |
| 2 | PFIZER INC | PFE | 717081103 | $42.7M | 5.71% | 1,771,743 | SH |
| 3 | VEEVA SYS INC | VEEV | 922475108 | $42.0M | 5.62% | 236,709 | SH |
| 4 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $39.0M | 5.22% | 682,005 | SH |
| 5 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $35.4M | 4.74% | 433,699 | SH |
| 6 | BAXTER INTL INC | BAX | 071813109 | $31.1M | 4.17% | 1,459,380 | SH |
| 7 | INSMED INC | INSM | 457669307 | $30.0M | 4.02% | 281,838 | SH |
| 8 | ZIMMER BIOMET HOLDINGS INC | ZBH | 98956P102 | $27.3M | 3.66% | 317,426 | SH |
| 9 | INSULET CORP | PODD | 45784P101 | $26.9M | 3.61% | 176,932 | SH |
| 10 | THERMO FISHER SCIENTIFIC INC | TMO | 883556102 | $26.0M | 3.49% | 51,934 | SH |
| 11 | ABBOTT LABORATORIES | ABT | 002824100 | $25.9M | 3.47% | 285,778 | SH |
| 12 | ASCENDIS PHARMA A/S | ASND | K08588103 | $25.3M | 3.39% | 94,843 | SH |
| 13 | SOLVENTUM CORP | SOLV | 83444M101 | $24.4M | 3.27% | 316,454 | SH |
| 14 | MEDTRONIC PLC | MDT | G5960L103 | $23.7M | 3.18% | 303,301 | SH |
| 15 | ELANCO ANIMAL HEALTH INC | ELAN | 28414H103 | $21.3M | 2.85% | 864,080 | SH |
| 16 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $20.3M | 2.72% | 546,848 | SH |
| 17 | ENVISTA HOLDINGS CORPORATION | NVST | 29415F104 | $19.1M | 2.56% | 726,108 | SH |
| 18 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $15.5M | 2.08% | 82,827 | SH |
| 19 | ICU MED INC | ICUI | 44930G107 | $15.5M | 2.07% | 105,700 | SH |
| 20 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $15.2M | 2.04% | 393,441 | SH |
| 21 | LANTHEUS HLDGS INC | LNTH | 516544103 | $14.7M | 1.97% | 132,662 | SH |
| 22 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $14.6M | 1.96% | 1,490,286 | SH |
| 23 | ELEDON PHARMACEUTICALS INC | ELDN | 28617K101 | $13.9M | 1.86% | 3,525,338 | SH |
| 24 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $12.0M | 1.61% | 376,870 | SH |
| 25 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $11.6M | 1.55% | 924,758 | SH |
| 26 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $11.3M | 1.52% | 1,047,690 | SH |
| 27 | LARIMAR THERAPEUTICS INC | LRMR | 517125100 | $11.2M | 1.50% | 3,670,135 | SH |
| 28 | GLOBUS MED INC | GMED | 379577208 | $11.0M | 1.48% | 139,637 | SH |
| 29 | ENOVIS CORPORATION | ENOV | 194014502 | $11.0M | 1.47% | 531,945 | SH |
| 30 | EVOMMUNE INC | EVMN | 30054Y107 | $10.5M | 1.41% | 793,145 | SH |
| 31 | TELEFLEX INCORPORATED | TFX | 879369106 | $10.2M | 1.36% | 80,118 | SH |
| 32 | DENALI THERAPEUTICS INC | DNLI | 24823R105 | $10.1M | 1.35% | 391,866 | SH |
| 33 | GLAUKOS CORP | GKOS | 377322102 | $9.3M | 1.24% | 66,519 | SH |
| 34 | STAAR SURGICAL CO | STAA | 852312305 | $9.2M | 1.24% | 322,126 | SH |
| 35 | PACS GROUP INC | PACS | 69380Q107 | $9.2M | 1.23% | 215,675 | SH |
| 36 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $9.0M | 1.20% | 239,440 | SH |
| 37 | LIVANOVA PLC | LIVN | G5509L101 | $8.8M | 1.18% | 107,373 | SH |
| 38 | BLACK DIAMOND THERAPEUTICS I | BDTX | 09203E105 | $3.1M | 0.41% | 1,674,999 | SH |
| 39 | MEREO BIOPHARMA GROUP PLC | MREO | 589492107 | $2.4M | 0.32% | 7,558,756 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $746.9M | 39 | 0002088557-26-000008 |
| 2026-03-31 | 2026-05-14 | $712.2M | 31 | 0002088557-26-000005 |
| 2026-03-31 | 2026-06-12 | $712.2M | 31 | 0002088557-26-000006 |
| 2025-12-31 | 2026-02-13 | $737.7M | 33 | 0002088557-26-000002 |
SUITE 625
EMERYVILLE, CA 94608